Featured Article
Attruby is the first and only approved treatment with a label specifying near-complete stabilization of Transthyretin (TTR).
Precision Oncology Today
Magazine
5 Key Startups Bringing Digital Pathology Into Focus
Digital pathology is driving precision medicine by turbocharging the analysis of tissue slides. Here are the five top startups turning microscopy into a data...
How Is Artificial Intelligence Changing the Clinical Trials Landscape?
There is no doubt that artificial intelligence (AI) is currently en vogue. Many AI and machine-learning applications are already being deployed in drug discovery and development. Not only can AI process, analyze, and interpret huge datasets, it can also be used for structural drug design and toxicity and efficacy predictions.
Trending on Inside Precision Medicine
Outreach Program Improves Colorectal Cancer Testing Rates
Mailing tests to people who need screening can help increase colorectal cancer test uptake rates in low-income communities.
New Method Shows Promise to Deliver Therapeutics Across the Blood-Brain Barrier
A new method safely and effectively delivers large therapeutic molecules into the brain—a discovery that could pave the way for treating a range of neurological and psychiatric disorders, including ALS, Alzheimer’s disease, and various forms of addiction.
BridgeBio’s Attruby Approved for Rare Heart Disease
Attruby is the first and only approved treatment with a label specifying near-complete stabilization of Transthyretin (TTR).
